BIOGEN INC. (BIIB)
@BIIB.asset
$151.44
At close:
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Figures
- Sector Healthcare
- Industry Biotechnology
- Index S&P 500
- Market Cap $22.22 B
- Last Earnings Report Oct 30, 2025
- Price Reaction to Earnings Report 2.11%
- Enterprise Value $24.54 B
- P/E ratio 13.77
- Price/Sales ratio 2.20
- EV/Sales ratio 2.44
- Price/Book Value 1.22
- Revenue $10.07 B
- EBIT $0.00 B
- Net Income $1.61 B
- Gross Profit $7.57 B
- Free Cash Flow $2.30 B
- EBIT Margin ?%
- Gross Margin 75.24%
- FCF Margin 22.89%
- Return on Equity 8.83%
- Equity Ratio 62.34%
- Debt/Equity Ratio 0.60
- 6-month Performance 24.33%
- 12-month Performance -12.86%
- Trend reversal good
What the community is saying
| Nobody said anything, yet! Speak your mind and be the first to create a new topic. |